This study investigated the 1-year incidence of extrapyramidal symptoms (EPS), as well as the incremental economic burden, in patients with schizophrenia initiating atypical antipsychotics. Objectives ...

EPSs are serious, debilitating and stigmatizing adverse effects that frequently require additional pharmacotherapy. 3 The two types of EPSs are as follows: early acute EPS, which most often develops ...

Background: Second-generation antipsychotics (SGAs) are thought to have a lower likelihood of inducing extrapyramidal symptoms (EPS) than are first-generation antipsychotics (FGAs). Clinical ...

Oct. 2, 2003 — Olanzapine was associated with the fewest patients with extrapyramidal symptoms (EPS) at six months compared with baseline, according to the results of a large prospective trial ...

Historical assumptions linking parkinsonism to therapeutic response have been displaced by evidence that antipsychotic efficacy is achievable without EPS, reframing tolerability as central to ...

New research illuminates the benefits and risks of antipsychotic medication in children and its impact on individual well-being, social, educational and/or vocational functioning, and disease burden.

This case highlights vitamin E’s potential as an effective adjunct treatment for patients with antipsychotic-induced motor symptoms resistant to standard therapies. Vitamin E has shown significant ...